{"product_id":"tuberculosis-and-the-tubercle-bacillus-isbn-9781555819552","title":"Tuberculosis and the Tubercle Bacillus","description":"\u003cp\u003e\u003cb\u003eCan today's innovative practices and molecular tools tame this ancient disease?\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOne third of the world's population is infected with tuberculosis (TB), with about 10 million new cases annually. To combat TB and its agent, Mycobacterium tuberculosis, the World Health Organization launched The End TB Strategy, which aims to slash the suffering and cost of TB by 2035.\u003c\/p\u003e \u003cp\u003eThis makes the second edition of \u003ci\u003eTuberculosis and the Tubercle Bacillus\u003c\/i\u003e, edited by Jacobs, McShane, Mizrahi, and Orme, an extremely valuable resource for scientists and clinicians. The editors have gathered their colleagues from around the world to present the latest on the molecular biology of \u003ci\u003eM. tuberculosis\u003c\/i\u003e and related species, the host-pathogen interactions that enable invasion, and the host's immune response to \u003ci\u003eM. tuberculosis\u003c\/i\u003e infection. The basic, clinical, and translational research presented in this book supports the goals of WHO's End TB Strategy by driving toward the development of effective vaccines, rapid molecular diagnostics, and anti-TB drugs.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eCreating an effective tuberculosis vaccine. Understand the innate and adaptive immune response to \u003ci\u003eM. tuberculosis\u003c\/i\u003e infection, its study in established animal models, and how this information is being used to develop new vaccines against TB.\u003c\/li\u003e \u003cli\u003eFormulating new antituberculosis drugs. Learn the challenges and methods for evaluating new drugs in preclinical trials with a focus on drugs that work against \"persisters\" and those that act on the electron transport complex and ATP synthase of \u003ci\u003eM. tuberculosis\u003c\/i\u003e.\u003c\/li\u003e \u003cli\u003eOvercoming the challenges of diagnosing tuberculosis. Review new diagnostic tools that are simple, rapid, affordable, specific, sensitive, and safe, including molecular-based diagnostic methods such as GeneXpert MTB\/RIF.\u003c\/li\u003e \u003cli\u003eUsing molecular, genomic, and bioinformatics tools to understand the biology and evolution of \u003ci\u003eMycobacterium\u003c\/i\u003e. Explore current research on the molecular mechanisms that \u003ci\u003eM. tuberculosis\u003c\/i\u003e uses to evade the immune system, enter a state of nonreplicating persistence, and become reactivated.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe second edition of \u003ci\u003eTuberculosis and the Tubercle Bacillus\u003c\/i\u003e presents the latest research on a microorganism that is exquisitely well adapted to its human host. This pathogen continues to confound scientists, clinicians, and public health specialists, who will all find much valuable information in this comprehensive set of reviews.\u003c\/p\u003e \u003cp\u003eContributors\u003c\/p\u003e \u003cp\u003ePreface\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I: Towards Edward Jenner’s Revenge: Developing an Effective Tuberculosis Vaccine \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eA. Basic Immunology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Innate Immune Responses to Tuberculosis\u003cbr\u003e\u003ci\u003eJeffrey S. Schorey and Larry S. Schlesinger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Cytokines and Chemokines in Mycobacterium tuberculosis Infection\u003cbr\u003e\u003ci\u003eRacquel Domingo-Gonzalez, Oliver Prince, Andrea Cooper, and Shabaana Khader\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Regulation of Immunity to Tuberculosis\u003cbr\u003e\u003ci\u003eSusanna Brighenti and Diane J. Ordway\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 The Memory Immune Response to Tuberculosis\u003cbr\u003e\u003ci\u003eJoanna R. Kirman, Marcela I. Henao-Tamayo, and Else Marie Agger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models\u003cbr\u003e\u003ci\u003eRandall J. Basaraba and Robert L. Hunter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eB. Animal Models\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6 Animal Models of Tuberculosis: An Overview\u003cbr\u003e\u003ci\u003eAnn Williams and Ian M. Orme\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Mouse and Guinea Pig Models of Tuberculosis\u003cbr\u003e\u003ci\u003eIan M. Orme and Diane J. Ordway\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Non-Human Primate Models of Tuberculosis\u003cbr\u003e\u003ci\u003eJuliet C. Peña and Wen-Zhe Ho\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Experimental Infection Models of Tuberculosis in Domestic Livestock\u003cbr\u003e\u003ci\u003eBryce M. Buddle, H. Martin Vordermeier, and R. Glyn Hewinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eC. Vaccines\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 Clinical Testing of Tuberculosis Vaccine Candidates\u003cbr\u003e\u003ci\u003eMark Hatherill, Dereck Tait, and Helen McShane\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eD. Human Immunology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11 Human Immunology of Tuberculosis\u003cbr\u003e\u003ci\u003eThomas J. Scriba, Anna K. Coussens, and Helen A. Fletcher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 The Immune Interaction between HIV-1 Infection and Mycobacterium tuberculosis\u003cbr\u003e\u003ci\u003eElsa du Bruyn and Robert John Wilkinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II: Drug Discovery and Development: State of the Art and Future Directions \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13 Preclinical Efficacy Testing of New Drug Candidates\u003cbr\u003e\u003ci\u003eEric L. Nuermberger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions\u003cbr\u003e\u003ci\u003eGregory M. Cook, Kiel Hards, Elyse Dunn, Adam Heikal, Yoshio Nakatani, Chris Greening, Dean C. Crick, Fabio L. Fontes, Kevin Pethe, Erik Hasenoehrl, and Michael Berney\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Targeting Phenotypically Tolerant Mycobacterium tuberculosis\u003cbr\u003e\u003ci\u003eBen Gold and Carl Nathan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III: Biomarkers and Diagnostics \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16 Tuberculosis Diagnostics: State of the Art and Future Directions\u003cbr\u003e\u003ci\u003eMadhukar Pai, Mark P. Nicol, and Catharina C. Boehme\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays\u003cbr\u003e\u003ci\u003eMadhukar Pai and Marcel Behr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Impact of the GeneXpert MTB\/RIF Technology on Tuberculosis Control\u003cbr\u003e\u003ci\u003eWendy Susan Stevens, Lesley Scott, Lara Noble, Natasha Gous, and Keertan Dheda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV: Host and Strain Diversity\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19 The Role of Host Genetics (and Genomics) in Tuberculosis\u003cbr\u003e\u003ci\u003eVivek Naranbhai\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 The Evolutionary History, Demography, and Spread of the Mycobacterium tuberculosis Complex\u003cbr\u003e\u003ci\u003eMaxime Barbier and Thierry Wirth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Impact of Genetic Diversity on the Biology of Mycobacerium tuberculosis Complex Strains\u003cbr\u003e\u003ci\u003eStefan Niemann, Matthias Merker, Thomas Kohl, and Philip Supply\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Evolution of Mycobacterium tuberculosis: New Insights into Pathogenicity and Drug Resistance\u003cbr\u003e\u003ci\u003eEva C. Boritsch and Roland Brosch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection V: The Signature Problem of Tuberculosis Persistence\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e23 Acid-Fast Positive and Acid-Fast Negative Mycobacterium tuberculosis: The Koch Paradox\u003cbr\u003e\u003ci\u003eCatherine Vilchèze and Laurent Kremer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions\u003cbr\u003e\u003ci\u003eRandall J. Basaraba and Anil K. Ojha\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Killing Mycobacterium tuberculosis In Vitro: What Model Systems Can Teach Us\u003cbr\u003e\u003ci\u003eTracy L. Keiser and Georgiana E. Purdy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Epigenetic Phosphorylation Control of Mycobacterium tuberculosis Infection and Persistence\u003cbr\u003e\u003ci\u003eMelissa Richard-Greenblatt and Yossef Av-Gay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 DNA Replication in Mycobacterium tuberculosis\u003cbr\u003e\u003ci\u003eZanele Ditse, Meindert H. Lamers, and Digby F. Warner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 The Sec Pathways and Exportomes of Mycobacterium tuberculosis\u003cbr\u003e\u003ci\u003eBrittany K. Miller, Katelyn E. Zulauf, and Miriam Braunstein\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 The Role of ESX-1 in Mycobacterium tuberculosis Pathogenesis\u003cbr\u003e\u003ci\u003eKa-Wing Wong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 The Minimal Unit of Infection: Mycobacterium tuberculosis in the Macrophage\u003cbr\u003e\u003ci\u003eBrian C. VanderVen, Lu Huang, Kyle H. Rohde, and David G. Russell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Metabolic Perspectives on Persistence\u003cbr\u003e\u003ci\u003eTravis E. Hartman, Zhe Wang, Robert S. Jansen, Susana Gardete, and Kyu Y. Rhee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Phenotypic Heterogeneity in Mycobacterium tuberculosis\u003cbr\u003e\u003ci\u003eNeeraj Dhar, John McKinney, and Giulia Manina\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Mycobacterium tuberculosis in the Face of Host-Imposed Nutrient Limitation\u003cbr\u003e\u003ci\u003eMichael Berney and Linda Berney-Meyer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eTuberculosis and the Tubercle Bacillus\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eSecond Edition \u003c\/p\u003e\u003cp\u003e\u003ci\u003eCan today's innovative practices and molecular tools tame this ancient disease?\u003c\/i\u003e \u003c\/p\u003e\u003cp\u003eOne third of the world's population is infected with tuberculosis (TB), with about 10 million new cases annually. To combat TB and its agent, Mycobacterium tuberculosis, the World Health Organization launched The End TB Strategy, which aims to slash the suffering and cost of TB by 2035. \u003c\/p\u003e\u003cp\u003eThis makes the second edition of \u003ci\u003eTuberculosis and the Tubercle Bacillus\u003c\/i\u003e, edited by Jacobs, McShane, Mizrahi, and Orme, an extremely valuable resource for scientists and clinicians. The editors have gathered their colleagues from around the world to present the latest on the molecular biology of \u003ci\u003eM. tuberculosis\u003c\/i\u003e and related species, the host-pathogen interactions that enable invasion, and the host's immune response to \u003ci\u003eM. tuberculosis\u003c\/i\u003e infection. The basic, clinical, and translational research presented in this book supports the goals of WHO's End TB Strategy by driving toward the development of effective vaccines, rapid molecular diagnostics, and anti-TB drugs. \u003c\/p\u003e\u003cul\u003e \u003cli\u003eCreating an effective tuberculosis vaccine.  Understand the innate and adaptive immune response to \u003ci\u003eM. tuberculosis\u003c\/i\u003e infection, its study in established animal models, and how this information is being used to develop new vaccines against TB.\u003c\/li\u003e \u003cli\u003eFormulating new antituberculosis drugs. Learn the challenges and methods for evaluating new drugs in preclinical trials with a focus on drugs that work against \"persisters\" and those that act on the electron transport complex and ATP synthase of \u003ci\u003eM. tuberculosis\u003c\/i\u003e. \u003c\/li\u003e\n\u003cli\u003eOvercoming the challenges of diagnosing tuberculosis. Review new diagnostic tools that are simple, rapid, affordable, specific, sensitive, and safe, including molecular-based diagnostic methods such as GeneXpert MTB\/RIF.\u003c\/li\u003e \u003cli\u003eUsing molecular, genomic, and bioinformatics tools to understand the biology and evolution of \u003ci\u003eMycobacterium\u003c\/i\u003e. Explore current research on the molecular mechanisms that \u003ci\u003eM. tuberculosis\u003c\/i\u003e uses to evade the immune system, enter a state of nonreplicating persistence, and become reactivated.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe second edition of \u003ci\u003eTuberculosis and the Tubercle Bacillus\u003c\/i\u003e presents the latest research on a microorganism that is exquisitely well adapted to its human host. This pathogen continues to confound scientists, clinicians, and public health specialists, who will all find much valuable information in this comprehensive set of reviews.\u003c\/p\u003e","brand":"ASM Press","offers":[{"title":"Default Title","offer_id":47990417752293,"sku":"NP9781555819552","price":130.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781555819552.jpg?v=1761787745","url":"https:\/\/k12savings.com\/es\/products\/tuberculosis-and-the-tubercle-bacillus-isbn-9781555819552","provider":"K12savings","version":"1.0","type":"link"}